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Abstract: The resident microbiome plays a key role in exposure of the upper gastrointestinal (GI)
tract mucosa to acetaldehyde (ACH), a carcinogenic metabolite of ethanol. Poor oral health is a
significant risk factor for oral and esophageal carcinogenesis and is characterized by a dysbiotic
microbiome. Dysbiosis leads to increased growth of opportunistic pathogens (such as Candida yeasts)
and may cause an up to 100% increase in the local ACH production, which is further modified by
organ-specific expression and gene polymorphisms of ethanol-metabolizing and ACH-metabolizing
enzymes. A point mutation in the aldehyde dehydrogenase 2 gene has randomized millions of alcohol
consumers to markedly increased local ACH exposure via saliva and gastric juice, which is associated
with a manifold risk for upper GI tract cancers. This human cancer model proves conclusively the
causal relationship between ACH and upper GI tract carcinogenesis and provides novel possibilities
for the quantitative assessment of ACH carcinogenicity in the human oropharynx. ACH formed from
ethanol present in “non-alcoholic” beverages, fermented food, or added during food preparation
forms a significant epidemiologic bias in cancer epidemiology. The same also concerns “free” ACH
present in mutagenic concentrations in multiple beverages and foodstuffs. Local exposure to ACH
is cumulative and can be reduced markedly both at the population and individual level. At best,
a person would never consume tobacco, alcohol, or both. However, even smoking cessation and
moderation of alcohol consumption are associated with a marked decrease in local ACH exposure
and cancer risk, especially among established risk groups.
Keywords: acetaldehyde; ADH; alcohol; ALDH; ALDH2; cancer; ethanol; fermented food; tobacco;
upper gastrointestinal tract
1. Introduction
Alcohol is a major risk factor for upper gastrointestinal (GI) tract cancer and exhibits a
dose-dependent effect on the incidence of oropharyngeal and esophageal squamous cell cancers [1].
A similar but weaker dose-risk relationship also exists with alcohol-related gastric cancer [1,2]. There
is no evidence that the ethanol molecule itself is genotoxic, mutagenic, or carcinogenic [3,4]. However,
its first metabolite, acetaldehyde (ACH), is a group 1 carcinogen to humans when associated with
consumption of alcoholic beverages [5]. The International Agency for Research on Cancer (IARC’s)
conclusion concerns metabolically formed ACH from ethanol and “free” ACH present in alcoholic
beverages [5,6]. Therefore, knowledge of all factors regulating ACH concentration in the upper GI
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tract is of essential importance for cancer prevention. In other alcohol-related cancers, such as liver and
female breast cancers, the carcinogenic mechanisms are different and by and large still hypothetical.
A point mutation in the aldehyde dehydrogenase 2 (ALDH2) gene results in deficient activity
of the main ACH-metabolizing mitochondrial enzyme (ALDH2) and proves conclusively the causal
relationship between local ACH exposure and upper GI tract cancers (Table 1; [7,8]). Bacteria and
yeasts present in the normal upper GI tract microbiome play a major role in local ACH formation
from ethanol present either in alcoholic beverages or food. Within seconds, alcohol ingestion results
in a dose-dependent accumulation of ACH in saliva. The prominent instant increase of salivary
ACH concentration is followed by a long-term phase, which lasts for as long as ethanol stays in
the human body. Host metabolism of ethanol and ACH are controlled by organ-specific expression
and gene polymorphisms of ethanol-metabolizing and ACH-metabolizing enzymes and contribute
to microbial ACH formation. The most important exogenous sources for local ACH exposure are
alcoholic beverages, tobacco, and alcohol-containing or ACH-containing (or both) “non-alcoholic”
beverages and food.
Table 1. Main characteristics of the gene mutation-based human model for the quantitative assessment
of acetaldehyde (ACH) carcinogenicity in alcohol-consuming aldehyde dehydrogenase (ALDH)
2-deficient subjects compared to ALDH2-active subjects [7,8].
â The ethanol molecule is neither genotoxic, mutagenic, nor carcinogenic
â ACH associated with alcohol consumption is a Group 1 human carcinogen
â ACH does not exist in saliva without the presence of ethanol or tobacco
â ACH accumulates after alcohol intake in about 2 times higher concentrations in saliva in
ALDH2-deficients than in ALDH2-actives
â The oropharynx and esophagus (?) as ideal target organs for quantification of ACH-related cancer risk
in humans
 In sharp contrast to the liver, the oral mucosa lacks low-KM ALDH enzymes and is thus unable to
eliminate acetaldehyde formed from ethanol
 The expression of ALDH enzymes is low in the esophagus, but their role in the regulation of local
ACH levels is still unknown
 The oral microflora has low or zero capacity to eliminate ACH
 Adequate data on salivary ACH in ALDH2-deficient subjects vs. ALDH2-active subjects;
equivalent data on ACH of the mucosal surface of the esophagus is still unavailable
 Adequate epidemiological data on the role of ALDH2 polymorphisms on the risk for
oropharyngeal cancer among never, moderate, and heavy drinkers
â No differences between ALDH2-deficient subjects and ALDH2-active subjects in confounding factors
hampering most epidemiological studies on alcohol-related cancer
 Smoking, diet, consumption of different beverages, varying drinking habits, underreporting, oral
hygiene levels, human papilloma virus (HPV), body mass index (BMI)
2. Acetaldehyde
2.1. Genotoxicity and Mutagenicity
In vitro and in vivo genotoxicity of ACH is generally accepted [3,5,9]. ACH fulfills four of the
ten key characteristics that are commonly exhibited by established human carcinogens [10]. ACH
is electrophilic and genotoxic, alters DNA repair, and induces oxidative stress. When administered
in relatively high concentrations in vitro, ACH causes DNA-protein crosslinks, DNA-strand breaks,
DNA adducts, sister chromatid exchanges, chromosomal aberrations, and micronuclei in eukaryotic
cells. In a study using pig liver DNA, ACH concentrations ranging from 100 to 500 µM in
the presence of polyamines resulted in an exponential increase of mutagenic ACH-DNA adduct
(1,N2-propanodeoxyguanosine) formation [11]. These ACH levels are relevant for prevailing salivary
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ACH concentrations after alcohol ingestion [12,13]. On the other hand, increased polyamine synthesis
is characteristic to regenerating oral and esophageal mucosa [14]. In 2015, the UK Committee on
Mutagenicity concluded that the weight of evidence for the in vitro mutagenicity of ACH has been
further strengthened, particularly with regard to generation of specific DNA adducts and induction of
micronuclei in mammalian cells at ACH concentrations realistically achievable from consumption of
alcoholic beverages [3].
Alcohol-treated ALDH2-knockout mice show increased levels of mutagenic ACH-DNA adducts
in the tongue, submandibular glands, esophagus, stomach and liver [15–17]. Furthermore, Japanese
alcoholics deficient in the ability to detoxify ACH (ALDH2 deficiency) combined with enhanced
ability to produce ACH from ethanol (highly active alcohol dehydrogenase [ADH] enzyme) show
markedly enhanced DNA damage characterized by elevated levels of N2-ethylidene-dG adducts in
blood DNA [18].
A 12-fold to 16-fold increase in mutagenic ACH-DNA adducts (N2-ethylidene-dG) has been
demonstrated in mouthwash samples of healthy human volunteers at 2 and 4 h after ingestion of a
moderate dose of alcohol aimed to reach 0.7h blood alcohol concentration [19]. In an alcohol sipping
model (diluted vodka at 5 min intervals) used in that study, salivary ACH concentration can be
assumed to have been approximately 150 µM (maximum 260 µM) for the first 20 to 40 min followed
by a rapid decrease to 20 to 30 µM for the remainder of the follow-up period (350 min) [8]. Mutagenic
ACH concentration has been estimated to range from 40 to 100 µM [20].
The formation of mutagenic ACH-DNA adducts in oral mucosa has been confirmed in rhesus
monkeys exposed to alcohol over their lifetimes [21]. In contrast to these findings, alcohol drinking
did not appear to induce significantly increased levels of N2-ethylidene-dG adducts in blood white
cells of human volunteers [22,23]. This discrepancy, however, is not surprising, since only very low
ACH concentrations are found in hepatic venous blood of intoxicated non-alcoholic male Caucasians,
and ACH levels are undetectable (<2 µM) in peripheral blood samples [24,25].
2.2. Carcinogenicity in Experimental Animals
There is sufficient evidence for the carcinogenicity of ACH in experimental animals [26].
In inhalation toxicity studies with rats, ACH vapor for up to 28 months produced adenocarcinomas of
the olfactory epithelium at all exposure concentrations and squamous cell carcinomas of the respiratory
epithelium at the two highest ACH levels [27,28]. Exposure to ACH vapor for 52 weeks produced
nasal and laryngeal carcinomas in Syrian golden hamsters [29]. Without an obvious dose-response
relationship, lifetime administration of ACH in drinking water to rats resulted in increased number
of pancreatic adenomas, lymphomas, leukemias, uterine and mammary gland adenocarcinomas,
and head osteosarcomas [30].
2.3. Carcinogenicity in Humans
Case reports and epidemiological studies on the carcinogenicity of ACH in humans without the
presence of ethanol are very limited. Nine cases of malignant neoplasms were reported among an
unspecified number of workers in an aldehyde factory in the German Democratic Republic between
1967 and 1972 [31]. Of the cancers found, five were bronchial tumors and two were carcinomas of
the oral cavity. The authors stated that the relative frequencies of these tumors were higher than the
expected frequency in the German Democratic Republic.
However, present epidemiologic and biochemical evidence on ALDH2-deficient individuals
provides a unique and quantifiable ACH exposure model in humans, the kind of which is not available
for any other of the group 1 carcinogens (Table 1, [7,8]). Nature has “randomized” millions of alcohol
consumers to markedly elevated local ACH concentrations via saliva every time when drinking alcohol.
The enhanced ACH exposure via saliva continues for as long as alcohol stays in blood circulation. Both
of these factors can be quantified and linked to the risk for oropharyngeal cancer in relation to the
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amount of alcohol consumed daily. Most importantly, the model is not biased by confounding factors
that hamper most epidemiological studies on alcohol-related cancer.
2.3.1. ALDH2-Deficiency as a Unique Human Cancer Model
A single point mutation in ALDH2 gene results in deficient activity of the main ACH metabolizing
low KM mitochondrial enzyme (ALDH2). Consequently, ALDH2-deficient subjects are exposed in the
presence of alcohol two to three times (via saliva) and five to six times (via gastric juice) higher ACH
concentrations than those with the active ALDH2 enzyme [32–36]. Parallel to increased local ACH
exposure, the risk of ALDH2-deficient alcohol drinkers for oral, pharyngeal, esophageal, and gastric
cancer is manifold compared to alcohol-consuming individuals with the active ALDH2-enzyme [37–43].
The mutated gene (ALDH2*487Lys allele) is derived from the ancient Pai-Yuei tribe, which was widely
distributed along the southeast coast of China up to Yunnan Province and the northern part of
Southeast Asia 2000–3000 years ago [44]. Today its carrier frequency is about 600 million people of
Eastern Asian descent [44,45]. Thus, ALDH2-deficiency is the most prevalent genetic health risk in
the world, passing in frequency to that of familial hypercholesterolemia (FH). The prevalence of FH is
1:200–250, but in contrast ALDH2 deficiency is 1:13 [44–46].
2.3.2. Quantitative Assessment of the Carcinogenicity of Acetaldehyde in Humans
The risk assessment for ACH has thus far relied on thresholds based on animal toxicology with
lower one-sided confidence limit of the benchmark dose values (BMDL), typically ranging between 11
and 63 mg/kg bodyweight (bw)/day depending on species and endpoint [7]. However, the animal data
is problematic due to poor study quality, problems in animal models, and relevance of the endpoint
(cancer linkage) in translation to humans [7]. According to BMDL modeling, ALDH2-deficient heavy
drinkers can be calculated to be exposed to a mean of 6.7 µg/kg bw/day of additional ACH via
saliva compared to ALDH2-active individuals [7]. This associates with odds ratios of up to seven for
esophageal and head and neck cancer [7]. These numbers derived from an ALDH2-deficient human
cancer model suggest markedly lower BMDL values for ACH (<0.1 mg/kg bw/day) than the ones
calculated from studies on experimental animals (11–63 mg/kg bw/day). Unfortunately, however,
human data does not allow for a dose-response-modeling as none of the epidemiological studies
provide absolute or extra risk data [7].
A simpler way is to calculate area under the curve (AUC) of local ACH exposure by multiplying
salivary ACH concentration with exposure time (Table 2). Based on five studies with uniform
results, salivary ACH concentration is a mean 1.1 mg/L higher in ALDH2-deficient subjects than in
ALDH2-active subjects for as long as alcohol stays in the human body after its intake [7]. On the basis
of the alcohol elimination rate (7 g/h), the increased exposure time to salivary ACH caused by the
deficient ALDH2 enzyme is 283 min in moderate drinkers and 660 min in heavy drinkers. The total
additional exposure of the oropharynx to ACH caused by ALDH2-deficiency is thus 311 mg/L/283 min
in moderate drinkers and 726 mg/L/660 min in heavy drinkers. According to one meta-analysis and
one well-performed study (total of 1189 cases and 3239 controls), ALDH2 deficiency is associated with
a 1.68-fold to 2.61-fold oropharyngeal cancer risk in moderate drinkers and 3.57-fold to 7.28-fold risk in
heavy drinkers [37,39]. The oropharyngeal cancer risk of ALDH2-deficient alcohol drinkers compared
with that of ALDH2-active individuals thus appears to have a dose-dependent correlation with the
additional local ACH exposure caused by the deficient ALDH2 enzyme [8].
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Table 2. Effect of ALDH2 deficiency, alcohol consumption, smoking, and certain foodstuffs on the
quantitative exposure of oropharynx to acetaldehyde (ACH) via saliva in relation to the risk for
oropharyngeal cancer. Calculations are based on selected examples as indicated in footers.
Exposure Model
Salivary ACH
Concentration
(mg/L; µM)
Exposure Time
(min)
ACH Exposure
(mg/L×min)/day
OR/RR for
Oropharyngeal
Cancer
ALDH2-Deficiency Model
- 3 doses (33 g ethanol)/day 1.1; 25 1 283 2 311 1 1.68–2.61 3
- 7 doses (77 g ethanol)/day 1.1; 25 1 660 2 726 1 3.57–7.28 3
1 Dose 40% Alcohol, no ACH 4
- Instant
3 × first 5 min 6.2; 150 15 93
1 × next 5 min 4.4; 100 5 22
instant total 115 1.29 5
- Long-term
20–80 min 0.88; 20 60 53
- Total
0–80 min 80 168
Smoking 6
- 1 cigarette 11.5; 261 5 58
- 3–5 cigarettes 11.5; 261 15–25 173–288 2.017
Yogurt
- Safest-case scenario 8 2.4; 55 3 7 ?
- Worst-case scenario 9 17.4; 395 3 × 5 261
Apple
- Safest-case scenario 10 0.3; 7 3 0.9 ?
- Worst-case scenario 11 2.4; 55 3 x 5 36
1 Difference in salivary ACH concentration (column 2) or in ACH exposure (column 4) (ALDH2-deficient
subjects—ALDH2-active subjects) [7]; 2 Based on the normal elimination rate of ethanol (7 g/h) [47]; 3 Odds
ratios (ORs) for oropharyngeal cancer, ALDH2-deficient subjects compared to ALDH2-active subjects [37,39];
4 One dose of alcohol is assumed to be ingested in three sips at 5-minute intervals staying each in the mouth
for about 5 s before swallowing. Adapted from [12,13,48]; 5 Relative risk (RR) of oropharyngeal cancer for 1
dose alcohol (10g ethanol)/day [49]; 6 Adapted from [50]; 7 OR for head and neck cancer in never drinkers
smoking > 3–5 cigarettes/day [51]; 8 One commercially available yogurt (approximately 150 mL)/day with
lowest reported ACH level, consumed in 3 min. Adapted from [52]; 9 Three commercially available yogurts
(approximately 3 × 150 mL)/day with highest reported ACH level, each consumed in 5 min. Adapted from [52];
10 One commercially available apple/day with lowest reported ACH level, consumed in 3 min. Adapted from [52];
11 Three commercially available apples/day with highest reported ACH level, each consumed in 5 min. Adapted
from [52]. ?: no data available.
Heavy alcohol drinking (ethanol ≥ 50 g/day) compared to non-drinkers and occasional drinkers
is associated with a 5.13-fold risk for oropharyngeal cancer [1]. From 50 g of ethanol, the human
body produces mathematically over 1 × 106 µmoles of ACH. Hepatic ALDH enzymes, however,
oxidize ACH formed from ethanol so effectively that after a moderate to high dose of alcohol
(0.4–1.2 g/kg) blood ACH levels are not detectable in healthy individuals with the normal ALDH2
enzyme [24,25,53]. In ALDH2-deficient individuals, blood ACH levels are only slightly elevated
(≤10 µM) [33,34,36]. In sharp contrast to the liver, the oral mucosa lacks low KM ALDH enzymes
and is thus unable to eliminate ACH formed from ethanol in the oral cavity [54]. The capacity of oral
microbes to eliminate ACH is also low, and in this respect, there is no evidence for any differences
between ALDH2-deficient and ALDH2-active individuals [55]. Therefore, alcohol drinking results
in the accumulation of mutagenic concentrations of ACH in the saliva of both ALDH2-active and
ALDH2-deficient individuals for as long as ethanol stays in the human body [12,13,33–36].
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2.3.3. Implications of the ALDH2 Cancer Model for Regulatory Authorities
There is no evidence that ACH derived from ethanol present sometimes in percentage
concentrations in “non-alcoholic” beverages or food is less carcinogenic to the upper GI tract mucosa
than ACH formed metabolically from the ethanol of official alcoholic beverages. This also concerns
ACH found in mutagenic concentrations in fermented foodstuffs or when present in the product
as a natural or added flavor [52,56]. There are no safe limits for very high (up to >1800 mg/L to
>45,000 µM) ACH concentrations measured in some alcoholic beverages [57,58]. This can be explained
at least in part due to the classification of ACH as a “generally recognized as safe” (GRAS) substrate
validated by the Joint Food and Agriculture Organization of the United Nations (FAO) and World
Health Organization (WHO) Expert Committee on Food Additives (JECFA) in 1998 and the Japan
Flavour and Fragrance Materials Association (JFFMA) in 2015 [59,60]. Inappropriately, the decision tree
for the safety assessment of flavoring substances applied by JECFA, JFFMA, the Flavour and Extract
Manufactures Association (FEMA) Expert Panel, and the European Food Safety Authority (EFSA) is
based on a misconception concerning ACH metabolism. The WHO model used by these authorities
predicts that ACH undergoes complete metabolism to safe products [59,61]. This assumption, however,
does not concern ACH, which accumulates in mutagenic concentrations in saliva in the presence of even
very low ethanol concentrations (10 mM, 0.5h [12,13]. Furthermore, a peak (up to 1000 µM) in salivary
ACH is seen instantly after sipping of alcoholic beverages containing high levels of ACH [13,36,62].
Genotoxic substances are generally not permitted for deliberate use in food production,
since there is an increased risk for cancer even at low exposure levels. Therefore, controlling
exposure levels to ALARA (EFSA) or ALARP (UK) (As Low as Reasonably Achievable or As Low
as Reasonably Practicable, respectively) are generally accepted principles concerning genotoxic,
mutagenic, and carcinogenic substances [10,63–65]. The scientific committee of EFSA has identified
within its priority tasks the development of justifiable approaches for the assessment of risks from
substances that are both genotoxic and carcinogenic [65]. To that aim, the ALDH2-deficiency model for
local ACH exposure in the human oropharynx provides a novel tool for the quantitative reevaluation
of ACH carcinogenicity in humans [7,8]. A key prerequisite for that approach will be that the amounts
of ethanol and ACH in beverages and foodstuffs are made generally available for researchers, health
care workers, regulatory authorities, and consumers.
3. Microbial Metabolism—A Major Source of Local Acetaldehyde in the Upper GI Tract
3.1. Salivary Acetaldehyde—Instant and Long-Term Exposure
Multiple factors contribute to salivary ACH levels (Figure 1). Normal human saliva does not
contain measurable levels of ACH without the presence of ethanol or tobacco [12,50]. After sipping a
small dose (5 mL) of 40% alcohol, ethanol is distributed to oral mucosal surfaces and saliva rapidly,
resulting in an up to 900 mM (4.4%) salivary ethanol concentration at 30 s [13,48]. Instant microbial
ACH formation from ethanol starts subsequently and continues for 5 to 10 min after each sip of alcohol
(Table 2; [13]). Certain members of the normal oral microflora possess particularly high ADH activity
and are able to dose-dependently produce ACH in vivo/in vitro in increasing ethanol concentrations
from 11 to 1500 mM (0.5h–7%) [12,66,67]. This indicates rather high KM values for specific microbial
ADHs and explains why in vivo salivary ACH concentrations are highest (up to 260 µM) immediately
after sipping of alcohol [13].
One dose of alcohol (10 g ethanol) daily is associated with a significant relative risk (RR) of 1.17
(approximately 20% increase) for oropharyngeal cancer [49,68]. Alcohol intake in three sips at 5-min
intervals is estimated to result in instant (mean approximately 115 mg/L/20 min) exposure of the
oropharynx to ACH, which represents close to 70% of the total (168 mg/L/80 min) ACH exposure
(Table 2, [13]). Long-term exposure (in this example approximately 53 mg/L/60 min) consists of ACH
formed from ethanol that is diffused into saliva from blood and lasts for as long as ethanol is present
in the human body [12]. High concentrations of “free” ACH present in some alcoholic beverages
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has been linked to the particularly high incidence of alcohol-related upper GI tract cancers [69–71].
This hypothesis is supported by biochemical findings showing that sipping of alcoholic beverages
containing “free” ACH from 470 µM to over 15.5 mM results in a short, 1 to 2 min peak (up to ≥1 mM)
in salivary ACH concentration [13,36,62]. Drinking habits, such as number of sips/dose and high ACH
concentration in the alcoholic beverage consumed may thus have a significant effect on the exposure
of oropharyngeal mucosa to ACH.
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Figure 1. Schematic overview of the major factors contributing to salivary acetaldehyde (ACH) levels
and therefore the local ACH exposure of oropharyngeal mucosa. ACH exposure leads to molecular
changes and mutagenesis, including DNA-adduct formation, DNA-protein crosslinks, DNA strand
breaks and chromosomal aberrations. Locally, these changes may lead to dysplasia and further into
oropharyngeal cancer. Microbial and host metabolism share the ability to convert ethanol to ACH by
the alcohol dehydrogenase enzyme (ADH). There is plethora of microbes that possess highly-active
ADH enzymes. However, the subs que t conversion of ACH to less ha ful sub tances seems to be
very limited due to the lack of active aldehyde dehydrogenase (ALDH) enzymes in both microbial and
oropharyngeal mucosal cells. In contrast to the human host, ethanol fermentation is a specific trait for
microbes. In low oxygen tensi n, sugars derived from dietary sou ces, such as gluc se and fructose, are
converted into ethanol and H is formed as a byproduct. The possible contribution of fermentative
pathways from glucose to local ACH production and further to ethanol has not been explored thus
far in vivo. In addition to alcoholic beverages and spirits, multiple dietary constituents can contain
ethanol, ACH, or both. There are also other sources of ethanol, such as hygiene products, including
daily oral mouthwash use. In addition to alcohol, tobacco is the major contributor to salivary ACH.
3.2. Oral and Esophageal Microbiome
As highlighted earlier, saliv ry ACH i mainly of microbial origin. There is a strong correlation
between in vivo and in vitro salivary ACH production [12]. 4-methylpyrazole (4-MP) is an effective
competitive inhibitor of the human ADH enzyme. Approximately 10 to 20 times higher 4-MP
concentrations are necessary for 40 to 50% inhibition of in vitro mi r bial ACH product on from ethanol
in saliva and oral bacterial lysates than for equal inhibition of ethanol elimination in humans [12,34,67].
In ALDH2-active subjects, 4-MP (10–15 mg/kg) did not reduce salivary ACH levels but decreased the
ethanol elimination rate by 46% [34]. This indicates the minor role of mucosal and glandular ADH and
the major role of microbial metabolism in the regulation of salivary ACH concentration after alcohol
intake. Furthermore, the use of chlorhexidine (CHX) antiseptic mouthwash for three days before intake
of a moderate dose of alcohol decreased the levels of salivary ACH significantly (approximately 50%)
in comparison with subjects that did not use CHX [12].
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3.2.1. Oral and Esophageal Microbiome in Health and Disease
Peak levels of ACH in saliva after alcohol ingestion can vary greatly between individuals (range
18–260 µM; [12,13]). These variations are due to compositional alterations in the oral microbiome and
levels of ethanol in saliva after alcohol ingestion. In the oral cavity, the interindividual variations in
microbial flora mainly occur at the species or strain level [72]. There are different intraoral habitats
(e.g., lateral, dorsal tongue, and the gingival pockets) characterized by various environmental variables.
Factors such as oxygen levels, nutrients, and type of surface structure (including squamous cell
epithelium and the enamel of the tooth) affect the microbial community structure and functional
outcomes. As elucidated by multiple microbiome studies, there is a highly diverse oral microbiome
in health, including over 700 bacterial species [73]. The bacterial community structure is dominated
by five phyla, including Firmicutes, Proteobacteria, Bacteroidetes, Actinobacteria, and Fusobacteria.
Streptococcus is the leading genus in the bacterial spectrum, followed by Prevotella, Veillonella, Neisseria,
and Haemophilus. The esophageal microbiome is a reflection of the oral microbial flora, broadly similar
in composition to the oral microbiome [74]. Unfortunately, the rich fungal flora that interacts with
bacteria in the upper GI tract is often overlooked in microbiome studies. As eukaryotes, fungi differ
in multiple ways from prokaryotic bacteria. Fungal cells are larger in size and have specific cell-wall
structures and advanced metabolic traits. The most common and well-studied are the Candida yeasts,
especially Candida albicans species. There are also other fungal members, such as Aspergillus, Malassezia,
and Rhodotorula, but their roles are widely unknown.
Poor oral health drives dysbiosis of the microbiome and is associated with dysplasia and
carcinogenesis in the upper GI tract [75–77]. Microbiota isolated from premalignant and oral
carcinoma sites have shown marked production of ACH in vitro, thus providing support for local ACH
exposure [78]. In subjects with poor oral health, two-fold higher in vitro salivary ACH production
from ethanol can be detected compared to individuals with good oral hygiene [79]. Neisseria and
Streptococcus species not only dominate the bacterial microbiome in health but also in dysbiosis [80].
Neisseria and Streptococcus species can dose-dependently produce significant and mutagenic levels of
ACH in vitro from ethanol [66,67]. Also, other species belonging to the core oral microbiome (such
as Rothia and Prevotella) are able to produce marked quantities of ACH in vitro from ethanol [81].
The differences between species and genera are due to variations in bacterial ADH enzyme profiles.
Pavlova et al. studied alcohol metabolism in streptococci and reported that many streptococcal species
have highly active ADH but lack an active ALDH enzyme [55]. In certain species, ADH and ALDH
enzymes are in the same enzyme complex. Similarly, no active ALDH enzyme has been found in
Neisseria [67].
3.2.2. Candida Yeasts—A Major Contributor to Local Alcohol Metabolism
In addition to bacterial counterparts, the fungal flora (Candida genus in particular) is a major
contributor to local ACH exposure. The presence of Candida yeasts correlates significantly with high
salivary ACH levels in vitro [82]. Candida yeasts are opportunistic organisms and thus their number
increases in dysbiotic conditions (such as in individuals with poor oral hygiene or impaired immunity).
Both C. albicans and non-C. albicans species, such as Candida glabrata and Candida tropicalis, can produce
carcinogenic levels of ACH from ethanol in vitro [83,84]. To support the role of Candida yeasts in local
ethanol metabolism and its linkage to malignant transformation, C. albicans ADH mRNA expression
has been detected in oral dysplasia in vivo [85]. Furthermore, the virulence attributes of C. albicans and
ACH production have been shown to correlate with the presence of oral cancer [86]. Chronic Candida
infections have been linked to oral and esophageal carcinogenesis in susceptible individuals [87,88].
Candida yeasts are known for their fermentative traits, thus driving the metabolic flux from carbon
sources (such as glucose and fructose) into ACH and ethanol (Figure 1). Candida yeasts can produce
mutagenic levels of ACH from glucose in vitro [83,86]. Marttila et al. has shown that in low oxygen
tension, conditions characteristic of multiple niches in the oral cavity, ACH levels produced in vitro
from glucose by Candida can be orders of magnitude larger than when oxygen is present [78].
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3.2.3. Biofilm Lifestyle—The Preferred Mode of Microbial Growth in the GI Tract
Along the GI tract, the preferred lifestyle for microbes is the formation of biofilm communities.
Biofilms are organized microbial communities attached to host surfaces and encased in microbially
produced extracellular matrix. A well-known example of biofilms in the human body is dental plaque.
In the biofilm mode of growth, microbial metabolism differs from its planktonic counterpart due
to metabolic rewiring [89,90]. Fermentative growth is preferred especially in the deeper niches of
biofilm structures, as oxygen is not as easily available as at the surface. Hypoxic conditions are
common in multiple niches in the oral cavity, such as gingival pockets and the tongue. Due to these
factors, the fermentative trait is preferred by yeasts and bacteria in the oral cavity and esophagus.
Expression of genes related to ethanol metabolism is upregulated in C. albicans biofilms and high
in vitro ACH production is associated with the biofilm lifestyle in C. albicans [91]. C. albicans may affect
the site-specific bacterial flora within the biofilm and increase the number of anaerobic bacteria in
the site in vitro [92]. This may increase the local ACH accumulation due to microbial fermentation.
Unfortunately, past in vitro studies on microbial ACH production has mainly been performed using
planktonic cells, which poorly simulates the growth and metabolism of various microbes in vivo.
3.2.4. The Effect of Alcohol and Smoking on the Microbiome and Microbiome Ethanol Metabolism
Alcohol consumption, smoking, or both can alter the niche-specific microbiome composition
and contribute to changes in biofilm structures and the biofilm metabolome [93,94]. Interestingly, in
smokers the microbiota has a more potent ability to produce ACH from ethanol both in vitro and
in vivo [50,79,95,96]. This may be due at least in part to selection of more ACH-tolerant species within
the biofilms. In alcoholics, yeast overgrowth (in particular Candida) has been reported in vivo [97].
As shown in Russian and Japanese study populations, the gut microbiota in alcoholics differs from
healthy controls with functional changes in microbial ethanol metabolism [98,99]. It remains to be
studied whether similar changes also occur in the upper GI tract microflora. These compositional and
functional changes, in combination with aberrant barrier function of the gut linked to alcohol use, can
contribute to increased ACH exposure and provide a basis for local ACH-related carcinogenesis.
3.3. Gastric Microbiome
The stomach has long been considered a sterile environment due to low pH. However, novel
studies have revealed that a core microbiome exists in a healthy acidic stomach as well [100–102].
The role of pH is critical in terms of balance in the gastric microbiome. A significant microbial
overgrowth and dysbiosis exists in the stomach of patients suffering from hypochlorhydria or
achlorhydria [103,104]. Hypochlorhydria or achlorhydria is usually due to atrophic gastritis or
the use of acid-suppressive medication. Recently, Imhann et al. described a significant increase
of genera ubiquitous in the oral microbiome (including Streptococcus and Rothia) in the gut of patients
using acid-suppressive medication [105]. Under anaerobic conditions prevailing in some parts of
a low-acid stomach and in the presence of glucose, bacterial colonization has been reported to
result in an ethanol concentration up to 27 mM (1.3h) and a maximum ACH concentration of
15.7 µM [106,107]. Väkeväinen et al. used culture-dependent techniques to identify the flora responsible
for ACH production in hypochlorhydric patients [108]. Various anaerobic and aerobic bacteria as
well as fungal species were identified [108]. The microbiome was rich in taxa and resembled the oral
microbiome. The most numerous and prevalent species isolated were Streptococcus, Stomatococcus,Neisseria,
and Corynebacterium species. High microbial ADH activities and low KM values were determined for
multiple species, thus supporting the potential for high local ACH production and exposure. More
novel studies using culture-independent methods have shown the resemblance of microbial flora in
various cancer-predisposing stages of stomach and gastric cancer with oral flora [109,110].
Helicobacter pylori, atrophic gastritis, alcohol consumption, tobacco smoking, acid-suppressive
drugs, ALDH2-deficiency associated with alcohol consumption, pickled foods, fermented soy foods,
Cancers 2018, 10, 11 10 of 23
and some fermented dairy products are risk factors for stomach cancer [1,2,38,43,111–117]. ACH
is a common local denominator of all of these cancer risk factors or conditions. In the presence of
alcohol, the intragastric ACH production in patients with hypochlorhydria or achlorhydric stomach
secondary either to atrophic gastritis or the use of acid suppressive drugs is increased to mutagenic
levels [32,107,108,118,119].
H. pylori is a core pathogen of the stomach. The presence of H. pylori leads to a decrease in the
diversity of gastric flora. It is the most important etiologic factor for atrophic gastritis and gastric
cancer, and is thus regarded as a group 1 human carcinogen by the IARC [120]. Many H. pylori
strains possess an active ADH enzyme and can produce markedly high amounts of ACH from ethanol
in vitro [121,122]. Under low oxygen tension, H. pylori might contribute to local ACH production
through fermentation [123]. However, the in vivo ACH-related effects of H. pylori on metaplasia,
dysplasia, and carcinogenesis are still unknown.
4. Host Metabolism of Ethanol and Acetaldehyde in the Upper GI Tract
Host metabolism of ethanol and ACH may contribute to microbial ACH formation from ethanol.
These metabolic pathways are regulated differently by varying organ-specific expression of ADH,
ALDH, and cytochrome P450 2E1 (CYP2E1) enzymes. In addition, gene polymorphisms have an effect
on the activities of enzymes that metabolize ethanol and ACH.
4.1. Oral Mucosa and Salivary Glands
The human oral mucosa has minor ADH activity, 10% of that of the esophagus and ~6% of that in
the liver [54,124]. Therefore, the role of mucosal ADH in ACH production from ethanol in saliva is
presumably negligible compared with that of microbes (see Section 3.2). Buccal mucosa also expresses
CYP2E1 [125]. However, the possible contribution of CYP2E1 to salivary ACH concentration in the
presence of ethanol is not known. The oral mucosa lacks both cytoplasmic and mitochondrial low KM
ALDH enzymes [54]. This important characteristic apparently plays a decisive role in the accumulation
of ACH in saliva after alcohol consumption.
There is strong evidence that after alcohol consumption the additional ACH is secreted in saliva in
ALDH2-deficient individuals from the salivary glands. Sixty minutes after a moderate dose (0.5 g/kg)
of alcohol, three Asian ALDH2-deficient volunteers (heterozygous for the mutant ALDH2*2 allele) had
markedly elevated ACH levels (3.9–75.0 µM) in their sterile parotid gland saliva [33]. In sharp contrast,
there was no measurable ACH in the parotid gland saliva from three ALDH2-active volunteers [33].
Furthermore, 4-MP, a powerful inhibitor of the human ADH enzyme, almost entirely prevented the
ethanol-induced increase in salivary ACH in ALDH2-deficient subjects but not in those with the normal
ALDH2 enzyme [34]. Finally, it was shown that ALDH2 deficiency has no effect on salivary ACH
concentration without the presence of ethanol in the systemic blood circulation [48]. These findings
indicate that ethanol is diffused to parotid glands from the blood circulation and is metabolized there
to ACH. However, if the ALDH2 enzyme of the parotid glands is deficient, additional ACH is secreted
to saliva. It remains to be established whether submandibular salivary glands play a similar role in
additional ACH secretion in ALDH2-deficient individuals.
The ADH enzyme encoded by the ADH1C*1 allele metabolizes ethanol to ACH 2.5 times
faster than that encoded by the ADH1C*2 allele. In heavy alcohol drinkers, this polymorphism
is associated with increased risk for upper GI tract cancer [126]. In homozygotes, higher salivary ACH
concentrations were observed following alcohol ingestion than those in volunteers heterozygous for
ADH1C or homozygous for ADH1C*2 [127]. Among Japanese alcoholics, the ADH1B*2 allele encoding
the fast ethanol-metabolizing ADH enzyme does not have significant effect on salivary ACH levels in
the presence of ethanol as compared to those with the slow-metabolizing ADH1B*1/*1 genotype [35].
However, slow ADH may be associated with the prolonged presence of ethanol in blood and saliva
and thus also with extended exposure time of the upper GI tract mucosa to microbial ACH [35].
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4.2. Esophagus and Stomach
The regulation of ACH concentration in the esophagus in the presence of ethanol is much more
complex and far less understood than that in the oral cavity. ADH activity of the esophageal mucosa is
seven to twelve times higher than in the tongue and gingiva [54,128]. Furthermore, chronic alcohol
consumption appears to induce CYP2E1 in the esophageal mucosa [129]. In contrast to the oropharynx,
the esophageal mucosa also expresses some ALDH enzyme activity, which is ~3% of that in the
liver [128]. The role of this ALDH enzyme in the local detoxification of ACH in the esophagus is
not known. However, ALDH2 deficiency markedly and dose-dependently increases the risk for
esophageal cancer among alcohol consumers when compared with ALDH2-active subjects, which
indicates that the esophageal mucosa contributes significantly to the exposure of the esophagus to
carcinogenic ACH [40].
Gastric mucosal ethanol and ACH-metabolizing enzymes are responsible for a significant gastric
first-pass metabolism of alcohol. The stomach mucosa possesses ADH activity that represents one third
of that in the esophagus and ~8% of that in the liver [130,131]. The gastric mucosa also contains ALDH
enzymes with 2.2 times higher activity than in the esophagus and ~13% of that in the liver [130,131].
Furthermore, the gastric mucosa expresses some CYP2E1 activity [132]. However, the contribution of
these various ethanol-metabolizing systems to the regulation of gastric juice ACH levels in the presence
of alcohol is thus far unknown. In individuals with a normal acidic stomach and an active ALDH2
enzyme, intragastric alcohol infusion (0.5 g/kg) causes a slight increase in the ACH concentration of
gastric juice from zero level to a mean peak of 10.4 µM [32]. However, in ALDH2-deficient subjects, a
profound elevation to mutagenic ACH concentrations (mean peak 47.1 µM) was seen [32]. The highest
intragastric ACH levels (mean 63.9 µM, range 32.0–96.7µM) were found in ALDH2-deficient subjects
after seven-day treatment with an acid-suppressive drug (rabeprazole 10 mg b.i.d.) and intragastric
alcohol infusion [32]. The alcohol-induced marked increase in gastric juice ACH concentrations of
hypochlorhydric and achlorhydric patients, especially among ALDH2-deficient subjects, provides
strong evidence for the local carcinogenic potential of ACH in gastric carcinogenesis.
5. Exogenous Sources for Local Acetaldehyde Exposure
In alcoholic beverages, ethanol is a product of microbial fermentation. In the process, significant
amounts of “free” ACH can accumulate depending on the microbial flora and fermentation process
used in addition to distillation and preservation techniques. Certain alcohol spirits (such as fruit-based
liqueur and spirits, grappa, sherry, and calvados) have been reported to contain extremely high levels
of ACH (up to 1850 mg/L or approximately 45 mM) as a congener [57,58,62,71]. The high consumption
rates of such spirits in certain Central European countries, such as France, Italy, and Hungary, may
account for the unusually high local incidence of alcohol-related upper digestive tract cancers [69,71].
In addition, alcoholic beverages milder in terms of ethanol content (wine, beer, and cider) can contain
levels markedly above the mutagenic (40–100 µM) limit of ACH [57,58].
There are also other routes for ACH exposure. ACH is added industrially to various daily
products, including cosmetics and hygiene products. There has been discussion over the use of
alcohol-containing mouthwash in daily dental hygiene routines. A large meta-analysis by Boffetta et
al. reported that heavy use of alcohol-containing mouthwash is associated with a significant risk of
oral and oropharyngeal cancers (ORs of 1.11 and 1.28, respectively) [133].
It is often forgotten and overlooked that diet can be a major local source for both ACH and
ethanol. ACH can occur in food naturally, due to production processes, or added intentionally as
a flavor compound. There is a long history of fermentation in food preservation. Interestingly,
developments in food preservation techniques (i.e., emergence of refrigeration) has been shown to
inversely correlate with the incidence of gastric cancer in developing countries [134,135]. However,
there are still a plethora of undeveloped areas globally where conservative measures are used to
preserve food. An example of such area is in Northwestern Iran where the use of certain milk-based
products, cheeses, yogurt, and other domestic products have been found as independent risk factors for
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gastric cancer (Table 3, [117]). Although lactic acid is known as the major end product of fermentation,
significant amounts of ethanol and ACH may also accumulate due to microbial fermentative processes.
Ethanol concentration levels of 0.05 to 2.5% (10.5–525 mM) and even higher have been measured.
Products mentioned in the literature include homemade mead and beer, kefir, kimchi, mursik milk,
soy sauce, pickled food, and vinegar [56,136,137]. Mursik milk and pickled vegetables are examples of
products associated with increased risk of esophageal cancer (Table 3).
Table 3. Odds ratios (OR) and 95% confidence intervals (CI) for gastric and esophageal cancer in
relation to selected food habits based on epidemiological surveys from high-risk areas.
Type of Cancer Food Habit OR 95%CI p-Value
Esophageal Pickled vegetables
1 2.10 1.47–3.0 <0.001
Mursik milk 2 3.72 1.96–7.14 <0.001
Gastric
Pickled vegetables 3 1.52 1.37–1.68 <0.001
Yogurt 4 16.26 2.1–125.7 0.008
Cheese 4 15.05 1.6–137.0 0.01
Moldy food 4 1.92 1.2–3.0 0.004
Pickling liquid 4
Brine 4.76 2.2–10.4 <0.001
Vinegar + brine 3.34 1.6–7.0 0.002
1 Data based on a large meta-analysis from China [138]; 2 Fermented milk used in western Kenya, an area with high
incidence of esophageal cancer [56,139]. ORs have not been adjusted; 3 Data based on large meta-analysis including
several different countries, such as China, Korea, and Japan [114]; 4 Food habits in high-risk area for gastric cancer
in northeastern Iran with adjusted ORs [117].
Generally available commercial milk products (such as yogurt) and various fruits can also contain
ACH in concentrations above its mutagenic limit (40–100 µM; Table 2) [52]. However, compared
to alcohol-containing beverages and foodstuffs, the exposure time to ACH associated with the
consumption of this type of product is much shorter (Table 2). In the safest-case scenario for one
yogurt/day, the total daily exposure of oropharynx to ACH is 4.2% of that of one dose of alcohol.
The corresponding percentage for one apple/day is only 0.5%. In the worst case-scenario, however,
three yogurts (450 mL)/day with a particularly high ACH concentration (17.4 mg/L) would result
in ACH exposure close to that of five cigarettes daily (Table 2). In a number of epidemiological
studies, fermented food products have been established as risk factors for upper digestive tract
cancers [56,112,114,140].
Alcohol is also used as part of cooking and added to certain sauces and dressings, including
marinades, fondues, barbeque sauces, salads, and sushi. In contrast to common belief, alcohol
does not totally evaporate during cooking. According to a study, 4 to 85% of alcohol is retained in
food depending on the cooking procedure, with remaining ethanol concentrations of 0.06 to 4.21%
(13–884 mM) after cooking [141]. As mentioned earlier, such concentrations of ethanol can lead to
substantial ACH exposure locally.
ACH is one of the most abundant human carcinogens in tobacco [142,143]. Similarly, electronic
cigarettes and various other smoking cessation products also contain ACH [144]. During smoking,
salivary ACH level increases rapidly to a mean of 261 µM (11.5 mg/L) and remains elevated for as
long as smoking continues [50]. After smoking, salivary ACH rapidly declines to basal zero level.
The area under the salivary ACH curve for one cigarette is thus 58 mg/L/5 min and therefore the
cumulative amount for three to five cigarettes ranges from 173 to 288 mg/L/15 min or 25 min/day.
Individuals with no alcohol consumption history that smoke greater than three to five cigarettes/day
have a 2.01-fold (OR) increased risk for head and neck cancer ([51], Table 2). Smoking independently
increases the production of ACH from ethanol in saliva in vitro by 60–75%, and in combination with
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heavy drinking the increase in ACH production is up to 100% both in vitro and in vivo, especially in
individuals with poor oral hygiene [50,79].
6. Preventive Actions—Detection of Risk Groups
A key factor in cancer prevention is the identification of specific carcinogenic compounds and
possible risk groups. ACH is a specific, local, and cumulative carcinogen. On the other hand, several
environmental, genetic, disease-based, and even iatrogenic risk factors or conditions for upper GI tract
cancer can be identified (Table 4).
Table 4. Environmental, genetic, disease-based, and iatrogenic risk factors or conditions for upper GI
tract cancer and their effect on local acetaldehyde (ACH) exposure via saliva. Without the presence of
ethanol or tobacco, salivary ACH levels are under the detection limit (<2 µM, [12,50]). The estimated
concentration range of mutagenicity for ACH is 40–100 µM [20].
Environmental risk factors:
â Alcohol consumption:
 Instant exposure: Microbial formation of ACH from ethanol (up to > 260 µM) in saliva for
0–10 min after each sip of alcohol [13]
 Long-term exposure: Ethanol diffused to saliva from blood is oxidized mainly by oral microbes
to ACH (mean 25 µM) in saliva for as long as ethanol remains in the human body [12]
â Tobacco smoking:
 Mean 260 µM of ACH in saliva for as long as smoking continues [50]
â Smoking + drinking:
 Seven-fold increase in local ACH exposure via saliva [50]
â Chronic smoking and heavy drinking:
 Both modify oral flora resulting in approximately 100% increase in salivary ACH production
from ethanol both in vitro and in vivo [50,79]
â Foodstuffs containing alcohol or ACH or both:
 There is no evidence that ACH derived from ethanol or ACH-containing “non-alcoholic”
beverages and food (or both) is less carcinogenic than ACH derived from official alcoholic
beverages [7,8]
Gene polymorphism-based risk conditions:
â ALDH2 deficiency among alcohol-consuming East Asians [37,40]: Mean two-fold additional ACH
exposure via saliva and five-fold via gastric juice compared to ALDH2-active subjects for as long as
alcohol stays in the human body [32,33]
â Highly active ADH among Caucasians [126]: In homozygotes, significantly higher salivary ACH levels
following alcohol ingestion than in heterozygotes or in those with normal ADH [127]
Disease-based risk conditions:
â Poor oral hygiene [145,146]: Associated with 100% higher in vitro ACH production in saliva from
ethanol [95]
â Helicobacter pylori [115]: Produces ACH from ethanol at least in vitro [121,122]
â Atrophic gastritis [147]: Hypochlorhydric or achlorhydric stomach is colonized by oral microbes that
produce ACH from ethanol in mutagenic concentrations [107,108,118]
â APECED (autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy): Rare disease
characterized by chronic oral candidiasis and increased risk for oral cancer [84,88]
Iatrogenic risk conditions:
â Long-term use of drugs suppressing gastric acid secretion (PPIs, H2-blockers) [111]: Microbial
colonization of stomach results in enhanced local ACH production from ethanol [32,119]
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Alcohol and tobacco are overwhelmingly the most dominant risk factors for oropharyngeal
and esophageal cancer. Their common carcinogenic denominator is ACH. Furthermore, alcohol
consumption and smoking increase dose-dependently and synergistically both the exposure of upper
GI tract mucosa to ACH and organ-specific cancer risk.
However, with regard to alcohol and ACH-related upper digestive tract cancers, some important
questions still remain unanswered. Microbial formation of ACH from ethanol present in “non-alcoholic”
beverages, fermented food, or added to during food preparation forms a significant epidemiologic bias
in upper GI tract carcinogenesis [8,56,114,117,141]. The same also concerns “free” ACH sometimes
present in very high concentrations in commonly used alcoholic beverages and in mutagenic levels in
some fermented food products or when used as a flavoring substance [52,56–58].
The most effective means to improve the poor prognosis of upper GI tract cancers is to improve
recognition of risk conditions combined with early detection and treatment of precancerous conditions
and individual health education based on updated information on hereditary, organ-specific and
environmental risks. To that aim, key elements are regular checkups for good oral hygiene, appropriate
H. pylori and atrophic gastritis diagnostics and recognition of increased gastric cancer risk associating
with long-term use of drugs suppressing gastric acid secretion (Table 4). For example, it has been
estimated that if moderate or heavy drinking ALDH2 heterozygotes were instead only light drinkers,
53% of esophageal squamous cell carcinomas might be prevented in the Japanese male population [45].
Therefore, screening of ALDH2 deficiency by flushing questionnaire or ethanol patch test combined
with health education of those in the risk group has been recommended [45].
7. Minimization of Acetaldehyde Exposure
Considering the importance of cancer preventive measures, there are luckily ways to markedly
reduce the exposure of upper GI tract mucosa to ACH at both population and individual level.
7.1. Population Level
Despite strong evidence on the local carcinogenicity of ACH in humans and the ubiquitous
presence of ACH in our everyday life, the topic is poorly recognized among authorities and public
health providers responsible for cancer prevention and food safety. Accordingly, outdated cancer
risk assessments of ACH based on experimental animals need to be revised using uniform results
obtained from genetic, epidemiologic, and biochemical studies on ALDH2-deficient alcohol consumers
compared with ALDH2-active consumers [7,8]. Since there is no evidence that ACH exposure
associated with the use of “non-alcoholic” beverages and food is less carcinogenic than ACH associated
with the use of official alcoholic beverages, labeling of alcohol and ACH levels of commercially available
alcoholic and “non-alcoholic” beverages and foodstuffs should be mandatory.
Currently, knowledge of the key role of local ACH in the pathogenesis of upper GI tract
cancers is familiar only to a limited number of researchers working in the field. Therefore, updated
evidence-based education should be provided widely for researchers, nutritionists, and consumers.
In the near future, ALARA and ALARP should be overriding principles for the presence of ethanol
and ACH in the production of alcoholic and “non-alcoholic” beverages and foodstuffs.
7.2. Individual Level
One standard dose of alcohol or three to five cigarettes daily significantly increases the risk for
oropharyngeal cancer [49,51]. Therefore, it is vital to quit smoking, including electronic cigarettes,
and to limit alcohol consumption to as low as reasonably achievable. If heavy drinkers were moderate
alcohol consumers, the relative risk for oropharyngeal cancer would be 1.83 (instead of 5.13) and
the corresponding value for esophageal cancer would be 2.23 (instead of 4.95) [1]. It should also
be emphasized that individuals with normal ADH and ALDH2 enzyme profiles are not protected.
For example, the relative risk of esophageal cancer in heavy drinkers (>120 g/day) and smokers
(>30 g/day) is 149.1 as compared with never/light drinkers and smokers [148].
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Maintenance of good oral hygiene is associated with an up to 100% decrease in microbial ACH
production from ethanol both in vitro and in vivo [50,79,95]. Avoidance of beverages and foodstuffs
containing ethanol, ACH, or both will hopefully be possible when this information is made available
to consumers.
Exposure of the upper GI tract mucosa to ACH via saliva or gastric juice after alcohol administration
can be markedly decreased by using special drug formulations of slow-release L-cysteine. L-cysteine
is a semi-essential, natural, and safe sulfur-containing amino acid that inactivates ACH by binding
to it non-enzymatically. The compound formed, 2-methyl-thiazolidine-4-carboxylic acid (MTCA), is
excreted in the feces or metabolized to safe substances in the liver. A buccal tablet containing 100 mg
of slow-release L-cysteine eliminated 60% of ACH in saliva for 5.3 h after ingestion of a moderate
dose (0.8 g/kg) of alcohol [149]. A lozenge containing 5 mg or 2.5 mg of L-cysteine inactivates during
smoking 100% and 96% of salivary ACH, respectively [150].
After intragastric alcohol installation in patients with atrophic gastritis, 60 to 70% of gastric
juice ACH is eliminated by ingestion of two slow-release L-cysteine (100 mg) capsules [118,151].
A similar inactivation of ACH after alcohol administration can be found also both in ALDH2-active
and ALDH2-deficient individuals treated for one week with a proton pomp inhibitor (rabeprazole
10 mg b.i.d.) [32].
8. Conclusions and Future Directions
Local microbial, mucosal, and salivary gland ACH production in the oral cavity as well as “free”
ACH in multiple beverages and foodstuffs are considered to play important roles in the carcinogenesis
of alcohol-related upper GI tract cancers.
Microbial formation of ACH in mutagenic concentrations starts in saliva and in the gastric juice
of the achlorhydric stomach instantly after alcohol ingestion and continues for as long as ethanol is
present in the human body. The key role of the oral microbiome, bacteria in particular, has already
been well established in this process. The role of the fungal flora composition in the upper GI tract has
started to gain increased attention. In terms of ethanol and ACH metabolism, more effort is needed to
further characterize the fungal-bacterial metabolic interactions. Current evidence also underlines the
importance of microbial biofilms along the upper GI tract, which are complex high-order communities
with unique metabolic traits in comparison to planktonic microbes.
A point mutation in the ALDH2 gene provides a unique human cancer model for local ACH
exposure, the kind of which is not available for any other of the group 1 human carcinogens.
Accordingly, previous animal toxicology-based risk assessments of ACH need to be revised using
updated evidence from genetic-epidemiologic and genetic-biochemical studies on ALDH2-deficient
subjects compared with ALDH2-active subjects.
Smoking cessation and abstinence or moderation of alcohol consumption are key factors in
the prevention oropharyngeal and esophageal cancers. There is currently no evidence that ethanol
and ACH present in “non-alcoholic” beverages and food is less carcinogenic than ACH associated
with consumption of official alcoholic beverages. The same also concerns ACH present in very high
concentrations in some alcoholic beverages. Therefore, mandatory labeling of ethanol and ACH
concentrations of commercially available beverages and foodstuffs would be of vital importance for
researchers, health care workers, nutritionists, and consumers.
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